Daiichi Sankyo to use India-based subsidiary to distribute drug
TOKYO Daiichi Sankyo will use a generic drug maker it acquired months ago to distribute one of its hypertension drugs in India, the Japanese drug maker announced Tuesday.
Daiichi will allow Gurgaon, India-based Ranbaxy to promote and market Olvance (olmesartan medoxomil) for the Indian market under a licensing agreement.
“The launch of Olvance is a historic moment in the collaboration between Ranbaxy and Daiichi Sankyo,” Ranbaxy chairman, CEO and managing director Malvinder Mohan Singh said. “This marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India.”
Study: Anti-smoking medication effective treatment for patients with cardiovascular disease
ORLANDO, Fla. An anti-smoking drug normally prescribed to otherwise healthy people also works for people with cardiovascular disease, according to a study.
Study results presented Tuesday at the American College of Cardiology’s 58th Annual Scientific Session indicate that 47% of smokers with a history of cardiovascular disease who take Pfizer’s drug Chantix (varenicline) were able to quit without relapse for the first four weeks of treatment, compared to 13.9% who received placebo.
“These data are consistent with the findings from the pivotal varenicline trials, which showed that varenicline was more effective than placebo among smokers who were generally healthy,” lead study investigator, Harvard Medical School professor of medicine and director of the Tobacco Research and Treatment Center at Massachusetts General Hospital Nancy Rigotti stated. “This study demonstrates that varenicline is effective in helping smokers with cardiovascular disease quit smoking.”
Approximately 130,000 people die each year from smoking-related cardiovascular disease in the United States, constituting about one-third of all smoking-related deaths among adults aged 35 and older.
FDA approves vaccine for Japanese encephalitis
ROCKVILLE, Md. A viral disease mostly found in Asia but rare in the United States that kills as many as 15,000 people a year now has a vaccine.
The Food and Drug Administration approved British drug maker Intercell Biomedical’s Ixiaro, a vaccine for Japanese encephalitis. The mosquito-borne disease, which affects between 30,000 and 50,000 people each year, is sometimes found among civilians and military traveling between the United States and Asia.
Symptoms of JE include flu-like symptoms that can progress to high fever, neck stiffness, brain damage, coma and death.